[Efficacy, safety and compliance of long-term growth hormone (GH) replacement therapy in adults with GH deficiency].

Aim: To study efficacy, safety and compliance of GH therapy for 4 years in 18 GH deficient (GHD) adults [12 women; mean age 50.5 yrs (25-66 yrs)].

Methods: Clinical, biochemical and body composition (DXA) measurements were performed before and every year after GH therapy.

Hyperthyroidism due to secretion of human chorionic gonadotropin in a patient with metastatic choriocarcinoma.

A 26-year-old pregnant woman presenting with repeated episodes of vaginal bleeding, weight loss, and shortness of breath was diagnosed with choriocarcinoma with metastases to both lungs. Chorionic gonadotropin levels (hCG) were >2.5 x 10(6)mU/mL.

One year of GH replacement therapy with a fixed low-dose regimen improves body composition, bone mineral density and lipid profile of GH-deficient adults.

Objective: We have studied the effects on body composition and metabolism of a fixed low dose of growth hormone (GH), 0.6 IU (0.2 mg)/day, administered for 12 months to GH-deficient (GHD) adults.